These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 22728287)

  • 1. Tyrosine kinase signaling in fibrotic disorders: Translation of basic research to human disease.
    Beyer C; Distler JH
    Biochim Biophys Acta; 2013 Jul; 1832(7):897-904. PubMed ID: 22728287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies.
    Distler JH; Distler O
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i48-51. PubMed ID: 19995744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis.
    Grimminger F; Günther A; Vancheri C
    Eur Respir J; 2015 May; 45(5):1426-33. PubMed ID: 25745048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis.
    Chaudhary NI; Roth GJ; Hilberg F; Müller-Quernheim J; Prasse A; Zissel G; Schnapp A; Park JE
    Eur Respir J; 2007 May; 29(5):976-85. PubMed ID: 17301095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials.
    Qu K; Huang Z; Lin T; Liu S; Chang H; Yan Z; Zhang H; Liu C
    Front Pharmacol; 2015; 6():300. PubMed ID: 26834633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis.
    Daniels CE; Wilkes MC; Edens M; Kottom TJ; Murphy SJ; Limper AH; Leof EB
    J Clin Invest; 2004 Nov; 114(9):1308-16. PubMed ID: 15520863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
    Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
    J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.
    Buchdunger E; Cioffi CL; Law N; Stover D; Ohno-Jones S; Druker BJ; Lydon NB
    J Pharmacol Exp Ther; 2000 Oct; 295(1):139-45. PubMed ID: 10991971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis.
    Akhmetshina A; Venalis P; Dees C; Busch N; Zwerina J; Schett G; Distler O; Distler JH
    Arthritis Rheum; 2009 Jan; 60(1):219-24. PubMed ID: 19116940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
    Avramis IA; Laug WE; Sausville EA; Avramis VI
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The biology of signal transduction inhibition: basic science to novel therapies.
    Griffin J
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):3-8. PubMed ID: 11740801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia.
    Vuorinen K; Gao F; Oury TD; Kinnula VL; Myllärniemi M
    Exp Lung Res; 2007 Sep; 33(7):357-73. PubMed ID: 17849262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
    Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
    Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuation of fibrosis with selective inhibition of c-Abl by siRNA in systemic sclerosis dermal fibroblasts.
    Karimizadeh E; Motamed N; Mahmoudi M; Jafarinejad-Farsangi S; Jamshidi A; Faridani H; Gharibdoost F
    Arch Dermatol Res; 2015 Mar; 307(2):135-42. PubMed ID: 25527259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor.
    Panek RL; Lu GH; Klutchko SR; Batley BL; Dahring TK; Hamby JM; Hallak H; Doherty AM; Keiser JA
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1433-44. PubMed ID: 9400019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib).
    Wermuth PJ; Jimenez SA
    PLoS One; 2018; 13(5):e0196559. PubMed ID: 29718973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Receptor Tyrosine Kinase Signaling in Renal Fibrosis.
    Liu F; Zhuang S
    Int J Mol Sci; 2016 Jun; 17(5):. PubMed ID: 27331812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiproliferation effect of imatinib mesylate on MCF7, T-47D tumorigenic and MCF 10A nontumorigenic breast cell lines via PDGFR-β, PDGF-BB, c-Kit and SCF genes.
    Kadivar A; Kamalidehghan B; Akbari Javar H; Karimi B; Sedghi R; Noordin MI
    Drug Des Devel Ther; 2017; 11():469-481. PubMed ID: 28260860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine kinases in the pathogenesis of tissue fibrosis in systemic sclerosis and potential therapeutic role of their inhibition.
    Mendoza FA; Piera-Velazquez S; Jimenez SA
    Transl Res; 2021 May; 231():139-158. PubMed ID: 33422651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.